Abstract
miR-21 and let-7 are two of the most studied microRNAs (miRNAs), as the former is the most frequently upregulated and the latter is the most frequently down-regulated in cancer. In this short essay, we examine the convergence of miR-21 and let-7 in two major cancer pathways: Ras and NF-κB. miR-21 suppresses multiple targets to enhance the oncogenic action of Ras, while let-7 is a direct negative regulator of the Ras gene family. let-7 is proposed to repress the activation of NF-κB through down-regulation of Ras and IL-6, while miR-21 is demonstrated to enhance NF-κB activation by down-regulating Pten and thereby increasing the activity of Akt, a kinase known to promote the NF-κB pathway. Therefore, miR-21 and let-7 contravene each other in cancer and simultaneous targeting of both is an attractive therapeutic strategy against cancers exhibiting both Ras mutations and constitutive NF-κB activation.
Keywords: MicroRNA, Cancer, miR-21, let-7, Ras, NF-kB, oncogenic action, apoptosis, pathobiological, phylogenetic.
MicroRNA
Title:miR-21 and let-7 in the Ras and NF-κB Pathways
Volume: 1 Issue: 1
Author(s): Saibyasachi N. Choudhury and Yong Li
Affiliation:
Keywords: MicroRNA, Cancer, miR-21, let-7, Ras, NF-kB, oncogenic action, apoptosis, pathobiological, phylogenetic.
Abstract: miR-21 and let-7 are two of the most studied microRNAs (miRNAs), as the former is the most frequently upregulated and the latter is the most frequently down-regulated in cancer. In this short essay, we examine the convergence of miR-21 and let-7 in two major cancer pathways: Ras and NF-κB. miR-21 suppresses multiple targets to enhance the oncogenic action of Ras, while let-7 is a direct negative regulator of the Ras gene family. let-7 is proposed to repress the activation of NF-κB through down-regulation of Ras and IL-6, while miR-21 is demonstrated to enhance NF-κB activation by down-regulating Pten and thereby increasing the activity of Akt, a kinase known to promote the NF-κB pathway. Therefore, miR-21 and let-7 contravene each other in cancer and simultaneous targeting of both is an attractive therapeutic strategy against cancers exhibiting both Ras mutations and constitutive NF-κB activation.
Export Options
About this article
Cite this article as:
N. Choudhury Saibyasachi and Li Yong, miR-21 and let-7 in the Ras and NF-κB Pathways, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010065
DOI https://dx.doi.org/10.2174/2211536611201010065 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
Current Medicinal Chemistry CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
Current Cancer Drug Targets New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review
Current Drug Therapy Magnetic Resonance Imaging of Uncommon Hepatic Mesenchymal Tumours: Haemangioendothelioma and Angiosarcoma
Current Medical Imaging Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry BST-2 Expression in Human Hepatocytes is Inducible by All Three Types of Interferons and Restricts Production of Hepatitis C Virus
Current Molecular Medicine Techniques and Strategies to Analyze Neural Progenitor Cell Migration
Current Pharmaceutical Biotechnology Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents The Selective Packaging and Annealing of Primer tRNALys3 in HIV-1
Current HIV Research Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiotonic Steroids, Hypertension and Cardiovascular Disease
Current Hypertension Reviews